A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein

Journal of Biological Chemistry

Volumn 287, Issue 2, 2012, Pages 1406-1414

  Baldo, Barbara ^a   Weiss, Andreas ^a   Parker, Christian N ^a   Bibel, Miriam ^a   Paganetti, Paolo ^a,b   Kaupmann, Klemens ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINES; CELL TREATMENT; CELLULAR LEVELS; CHAPERONE FUNCTIONS; CO-IMMUNOPRECIPITATION EXPERIMENTS; CYCLOHEXIMIDES; DOMINANT NEGATIVE; EMBRYONIC STEM CELLS; ES CELLS; HEAT SHOCK PROTEIN; HEAT SHOCK RESPONSE; HEAT-SHOCK FACTOR 1; HIGH THROUGHPUT; HUNTINGTIN; HUNTINGTON DISEASE; MUTANT HUNTINGTIN; OVER-EXPRESSION; PHYSICAL INTERACTIONS; PROTEIN SYNTHESIS; RESONANCE ENERGY TRANSFER; TIME-RESOLVED; TOXIC EFFECT; UBIQUITIN-PROTEASOME SYSTEM; UP-REGULATION; WESTERN BLOTS; WILD TYPES;

AMINO ACIDS; BIOSYNTHESIS; CELL CULTURE; DEGRADATION; ENERGY TRANSFER; STEM CELLS;

PROTEINS;

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; CHAPERONE; CYCLOHEXIMIDE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; PEPTIDE FRAGMENT; PROTEASOME; UBIQUITIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENERGY TRANSFER; ENZYME INHIBITION; ENZYME REGULATION; HIGH THROUGHPUT SCREENING; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANIMALS; DNA-BINDING PROTEINS; HEK293 CELLS; HIPPOCAMPUS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MICE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RESORCINOLS; TRANSCRIPTION FACTORS; UBIQUITIN;

EID: 84855478434     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.294801     Document Type: Article

References (44)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983
2. Ross, C. A., and Tabrizi, S. J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98
3. Fecke, W., Gianfriddo, M., Gaviraghi, G., Terstappen, G. C., and Heitz, F. (2009) Small molecule drug discovery for Huntington's Disease. Drug Discov. Today 14, 453-464
4. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993
5. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., Manoharan, M., Sah, D. W., Zamore, P. D., and Aronin, N. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U.S.A. 104, 17204-17209
6. McBride, J. L., Boudreau, R. L., Harper, S. Q., Staber, P. D., Monteys, A. M., Martins, I., Gilmore, B. L., Burstein, H., Peluso, R. W., Polisky, B., Carter, B. J., and Davidson, B. L. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U.S.A. 105, 5868-5873
7. Sah, D. W., and Aronin, N. (2011) Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Investig. 121, 500-507
8. Yamamoto, A., Lucas, J. J., and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66
9. Turturici, G., Sconzo, G., and Geraci, F. (2011) Hsp70 and its molecular role in nervous system diseases. Biochem. Res. Int. 2011, 618127
10. Cummings, C. J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H. T., Dillmann, W. H., and Zoghbi, H. Y. (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet. 10, 1511-1518
11. Lotz, G. P., Legleiter, J., Aron, R., Mitchell, E. J., Huang, S. Y., Ng, C., Glabe, C., Thompson, L. M., and Muchowski, P. J. (2010) Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J. Biol. Chem. 285, 38183-38193
12. Muchowski, P. J., Schaffar, G., Sittler, A., Wanker, E. E., Hayer-Hartl, M. K., and Hartl, F. U. (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U.S.A. 97, 7841-7846
13. Taipale, M., Jarosz, D. F., and Lindquist, S. (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11, 515-528
14. Pratt, W. B., and Toft, D. O. (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228, 111-133
15. Rutherford, S. L., and Lindquist, S. (1998) Hsp90 as a capacitor for morphological evolution. Nature 396, 336-342
16. Luo, W., Sun, W., Taldone, T., Rodina, A., and Chiosis, G. (2010) Heat shock protein 90 in neurodegenerative diseases. Mol. Neurodegener. 5, 24
17. Kamal, A., and Burrows, F. J. (2004) Hsp90 inhibitors as selective anticancer drugs. Discov. Med. 4, 277-280
18. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., and Burrows, F. J. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410
19. Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M. K., Hartl, F. U., and Wanker, E. E. (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307-1315
20. Wacker, J. L., Huang, S. Y., Steele, A. D., Aron, R., Lotz, G. P., Nguyen, Q., Giorgini, F., Roberson, E. D., Lindquist, S., Masliah, E., and Muchowski, P. J. (2009) Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci. 29, 9104-9114
21. Paganetti, P., Weiss, A., Trapp, M., Hammerl, I., Bleckmann, D., Bodner, R. A., Coven-Easter, S., Housman, D. E., and Parker, C. N. (2009) Development of a method for the high-throughput quantification of cellular proteins. Chembiochem 10, 1678-1688
22. Weiss, A., Roscic, A., and Paganetti, P. (2009) Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction. Mol. Neurodegener. 4, 11
23. Lin, C. H., Tallaksen-Greene, S., Chien, W. M., Cearley, J. A., Jackson, W. S., Crouse, A. B., Ren, S., Li, X. J., Albin, R. L., and Detloff, P. J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10, 137-144
24. Ying, Q. L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., and Smith, A. (2008) The ground state of embryonic stem cell self-renewal. Nature 453, 519-523
25. Bibel, M., Richter, J., Lacroix, E., and Barde, Y. A. (2007) Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells. Nat. Protoc. 2, 1034-1043
26. Heldens, L., Dirks, R. P., Hensen, S. M., Onnekink, C., van Genesen, S. T., Rustenburg, F., and Lubsen, N. H. (2010) Co-chaperones are limiting in a depleted chaperone network. Cell. Mol. Life Sci. 67, 4035-4048
27. Ko, J., Ou, S., and Patterson, P. H. (2001) New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319-329
28. Weiss, A., Abramowski, D., Bibel, M., Bodner, R., Chopra, V., DiFiglia, M., Fox, J., Kegel, K., Klein, C., Grueninger, S., Hersch, S., Housman, D., Régulier, E., Rosas, H. D., Stefani, M., Zeitlin, S., Bilbe, G., and Paganetti, P. (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal. Biochem. 395, 8-15
29. Weiss, A., Grueninger, S., Abramowski, D., Giorgio, F. P., Lopatin, M. M., Rosas, H. D., Hersch, S., and Paganetti, P. (2011) Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. Anal. Biochem. 410, 304-306
30. Schilb, A., Riou, V., Schoepfer, J., Ottl, J., Müller, K., Chene, P., Mayr, L. M., and Filipuzzi, I. (2004) Development and implementation of a highly miniaturized confocal 2D-FIDA-based high-throughput screening assay to search for active site modulators of the human heat shock protein 90beta. J. Biomol. Screen. 9, 569-577
31. Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K. M., Collins, I., Davies, N. G., Drysdale, M. J., Dymock, B., Eccles, S. A., Finch, H., Fink, A., Hayes, A., Howes, R., Hubbard, R. E., James, K., Jordan, A. M., Lockie, A., Martins, V., Massey, A., Matthews, T. P., McDonald, E., Northfield, C. J., Pearl, L. H., Prodromou, C., Ray, S., Raynaud, F. I., Roughley, S. D., Sharp, S. Y., Surgenor, A., Walmsley, D. L., Webb, P., Wood, M., Workman, P., and Wright, L. (2008) 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 51, 196-218
32. Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven, B. A., Gowan, S., Boxall, F., Aherne, W., Rowlands, M., Hayes, A., Martins, V., Urban, F., Boxall, K., Prodromou, C., Pearl, L., James, K., Matthews, T. P., Cheung, K. M., Kalusa, A., Jones, K., McDonald, E., Barril, X., Brough, P. A., Cansfield, J. E., Dymock, B., Drysdale, M. J., Finch, H., Howes, R., Hubbard, R. E., Surgenor, A., Webb, P., Wood, M., Wright, L., and Workman, P. (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68, 2850-2860
33. Johnson, J. L., and Toft, D. O. (1995) Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol. Endocrinol. 9, 670-678
34. Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J. P., Gusella, J. F., and Joyner, A. L. (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410
35. Kaarniranta, K., Oksala, N., Karjalainen, H. M., Suuronen, T., Sistonen, L., Helminen, H. J., Salminen, A., and Lammi, M. J. (2002) Neuronal cells show regulatory differences in the hsp70 gene response. Brain Res. Mol. Brain Res. 101, 136-140
36. Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M., and Sobue, G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088-1095
37. Tokui, K., Adachi, H., Waza, M., Katsuno, M., Minamiyama, M., Doi, H., Tanaka, K., Hamazaki, J., Murata, S., Tanaka, F., and Sobue, G. (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18, 898-910
38. Thomas, M., Harrell, J. M., Morishima, Y., Peng, H. M., Pratt, W. B., and Lieberman, A. P. (2006) Pharmacologic and genetic inhibition of hsp90- dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum. Mol. Genet. 15, 1876-1883
39. Labbadia, J., Cunliffe, H., Weiss, A., Katsyuba, E., Sathasivam, K., Seredenina, T., Woodman, B., Moussaoui, S., Frentzel, S., Luthi-Carter, R., Paganetti, P., and Bates, G. P. (2011) Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Investig. 121, 3306-3319
40. Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K. Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., and Kopito, R. R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704-708
41. Bowman, A. B., Yoo, S. Y., Dantuma, N. P., and Zoghbi, H. Y. (2005) Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum. Mol. Genet. 14, 679-691
42. Hunter, J. M., Lesort, M., and Johnson, G. V. (2007) Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res. 85, 1774-1788
43. Ortega, Z., Díaz-Hernández, M., Maynard, C. J., Hernández, F., Dantuma, N. P., and Lucas, J. J. (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J. Neurosci. 30, 3675-3688
44. Bett, J. S., Goellner, G. M., Woodman, B., Pratt, G., Rechsteiner, M., and Bates, G. P. (2006) Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum. Mol. Genet. 15, 33-44